Specific high-affinity binding sites for non-steroidal anti-oestrogens such as tamoxifen have been identified in many animal and human tissues. The function of these binding sites and the nature of their endogenous ligands are currently unknown. Our laboratory has previously reported that unsaturated fatty acids at micromolar concentrations inhibited [3H]tamoxifen binding to the anti-oestrogen-binding sites in rat liver, raising the possibility that fatty acids might represent endogenous ligands for these sites. These studies have now been extended to examine the mechanism by which fatty acids inhibit [3H]tamoxifen binding to the anti-oestrogen-binding site. Saturation analysis revealed that increasing concentrations of oleic acid progressively decreased the apparent binding affinity of these sites for [3H]tamoxifen without decreasing the total number of binding sites; however, the apparent dissociation constant did not vary linearly with the prevailing oleic acid concentration, suggesting that the inhibition of [3H]tamoxifen binding by fatty acid was not competitive in nature. Kinetic studies of [3H]tamoxifen binding showed that oleic acid did not affect the rate ofassociation, but increased the rate ofdissociation of[3H]tamoxifen from the anti-oestrogen-binding site; the latter finding would not be expected if oleic acid acted as a competitive inhibitor. Furthermore, incubation of a rat microsomal fraction with [3H]oleic acid in the absence and presence of excess non-radioactively labelled tamoxifen also failed to demonstrate direct competition between oleic acid and tamoxifen for the same binding site. It is concluded that oleic acid, and presumably other unsaturated fatty acids, do not compete for the anti-oestrogen-binding site and probably reduce its tamoxifen-binding affinity by some other mechanism, such as pertubation of the lipid environment of the binding site. The biological significance of this interaction of unsaturated fatty acids with the anti-oestrogen-binding site remains to be elucidated.
INTRODUCTION
Specific high-affinity binding sites for the triphenylethylene anti-oestrogens such as tamoxifen, distinct from oestrogen receptors, have been identified in many normal animal and human tissues (Sutherland et al., 1980; Gulino & Pasqualini, 1982; Faye et al., 1983; Kon, 1983; Sudo et al., 1983) as well as in malignant cells (Miller & Katzenellenbogen, 1983; Watts et al., 1984; Kon, 1985) . The function of these binding sites is currently unknown, and their possible role in mediating the biological effects of the non-steroidal anti-oestrogens remains controversial (Miller & Katzenellenbogen, 1983; Murphy & Sutherland, 1983; Sheen et al., 1985) . It has been proposed that endogenous ligands for these sites may exist (Clark et al., 1983; Murphy et al., 1984) , and several laboratories have attempted to identify ligands for these sites by looking for endogenous substances capable of inhibiting [3H]tamoxifen binding to these sites. Murphy et al. (1985) , for example, demonstrated that oxygenated metabolites of cholesterol inhibited [3H]tamoxifen binding to anti-oestrogen-binding sites in chicken liver, whereas Brandes et al. (1985) reported that histamine antagonists competed for these sites in rat liver and suggested that histamine or histamine-like substances might represent endogenous ligands. Our laboratory recently showed that unsaturated fatty acids at micromolar concentrations were also capable of inhibiting [3H] tamoxifen binding to these sites (Hwang, 1986) . It would be premature, however, to postulate that any of these substances might represent endogenous ligands, since none has been shown to bind directly to the anti-oestrogen-binding sites. Indeed, there are no studies to date on the mechanisms by which these various substances inhibit [3H]tamoxifen binding. The studies reported here were carried out to examine the mechanism by which unsaturated fatty acids inhibit [3H] tamoxifen binding to these sites.
MATERIALS AND METHODS Chemicals
[N-methyl-3H]Tamoxifen (87 Ci/mmol) was obtained from Amersham International and stored in ethanol at -20°C protected from light. [3H]Oleic acid (35 Ci/mmol) was obtained from New England Nuclear and stored under similar conditions. Tamoxifen citrate, diethylstilboestrol and fatty acids were from Sigma Chemical Co. Bio-Gel A-0.5 m (10% agarose) was from Bio-Rad. All other chemicals were of analytical grade and were purchased from conventional sources. Tissue preparation A 20000 g supernatant from rat liver, which contained anti-oestrogen-binding sites, was prepared and stored Vol. 243 Trivial names used: tamoxifen, (Z)-2-[p-(1,2-diphenylbuten-1-yl)phenoxy]-NN-dimethylethylamine; oleic acid, cis-9-octadecenoic acid.
as previously described (Hwang, 1986) . Appropriate dilutions were made with ice-cold buffer [10 mM-Tris/ HCI/ 1.5 mM-EDTA/20 mM-sodium molybdate/ 10 % (v/v) glycerol, pH 7.5 at 4°C] for the various studies described below.
Ligand-binding assay
Unless otherwise stated, this was carried out as described previously (Hwang, 1986) .
Saturation analysis of 13Hltamoxifen binding in the absence and presence of fatty acid Saturation analysis was carried out by incubating the rat liver 20000 g supernatant (0.5 ml; protein concentration 0.7 mg/ml) with various concentrations of [3H]tamoxifen (0.15-5.0 nM) for 16 h at 4°C in the absence or presence of 10, 20, 30, and 40 juM-oleic acid. To terminate the assay, 0.25 ml of dextran-coated charcoal [10 mM-Tris/HCl/10% (v/v) glycerol/0.25 % Norit A/charcoal/0.025% dextran T70, pH 7.5 at 4°C] was added. The charcoal was pelleted by centrifugation at 1500 g for 15 min and the supernatants were counted for radioactivity as previously described (Hwang, 1986) . Non-specific binding was determined by parallel incubations in the presence of a 500-fold molar excess of non-radioactively labelled tamoxifen. For comparison, a similar analysis was carried out using 1, 2, 4 and 8 nM non-radioactively labelled tamoxifen in place of oleic acid.
Association and dissociation studies
For these studies, which were carried out at 4°C, the 20000 g rat liver supernatant was diluted to a final protein concentration of 0.5-1.0 mg/ml with buffer. Diethylstilboestrol was added to a final concentration of 1 /M to eliminate binding to oestrogen receptors.
For the association studies, 4.0 ml of rat liver supernatant was mixed with oleic acid ( k-1 = In 2/t Gel filtration A 1 ml sample of rat liver 20 000 g supernatant diluted 10-fold with buffer (final protein concentration 0.7 mg/ml) was incubated at 4°C for 16 h with approx. 250000 c.p.m. of [3H]tamoxifen (2.5 nM) in the absence or presence of 2.5 /M-tamoxifen or 500 ,LM-oleic acid. Chromatography was carried out on a Bio-Gel A-0.5 m column (10% agarose; 1.6 cm x 30 cm) equilibrated with 10 mM-Tris/HCI (pH 7.5)/1 .5 mM-EDTA/20 mM-sodium molybdate/10%IO (v/v) glycerol. Fractions (2.6 ml) were collected and counted for radioactivity. An identical experiment was carried out with [3H]oleic acid (6 nM) in place of [3H]tamoxifen.
Other procedures
Protein was determined by the method of Lowry et al. (1951) , with bovine serum albumin as standard. Other studies were carried out as described in the appropriate Figure The presence of oleic acid did not significantly alter the number of binding sites (horizontal intercept), but clearly decreased the binding affinity (slope) in a dose-dependent manner. In the presence of 10, 20, 30 and 40,M-oleic acid, the apparent equilibrium dissociation constant increased from 0.77 nm to 1.00, 1.14, 2.43 and 3.56 nm respectively. If the change in the apparent binding affinity for [3H]tamoxifen was due to competition by oleic acid, then the change in the apparent dissociation constant should fit the expression: Scatchard (1949) function of oleic acid concentration (1). This is clearly not the case (Fig. la, inset) , suggesting that some mechanism other than competitive inhibition is involved in the inhibition of [3H]tamoxifen binding by fatty acid. On the other hand, when saturation analysis was carried out in the presence of 0, 1, 2, 4 and 8 nm non-radioactive tamoxifen, Kd varied linearly with tamoxifen concentration (Fig. lb, inset) . This is expected, since tamoxifen competes directly with [3H]tamoxifen for the same binding site.
To determine whether the increase in the apparent equilibrium dissociation constant seen in the presence of oleic acid is due to a decrease in the association rate or an increase in the dissociation rate, or both, kinetic studies were carried out. Fig. 2 shows the results of a representative experiment performed to determine the association rate constant. Fig. 2(a) significantly at equilibrium (Hwang, 1986) . Fig. 2(b) shows the plots for the determination of the association rate constants in the absence and presence of oleic acid. The rate of association for brief reaction times, during which dissociation is negligible, may be considered as that of a second-order irreversible reaction, and determined as described in the Materials and methods section. The association rate constants in the presence of 0, 25 and 50,aM-oleic acid, obtained by measuring the slopes of the plots in Fig. 2 , were 8.0 x 105, 8.0 x 105 and 7.5 x I05 M-1 -s-1 respectively. From four separate experiments the association rate constants (mean+ S.D.) in the presence of 0, 25 and 50 #uM-oleic acid were 8.1 + 0.6, 9.3 +0.9 and 9.0+ 1.3 x 105 M-15 s-respectively; the differences were not statistically significant (P > 0.05). Fig. 3 shows the dissociation of [3H]tamoxifen from the anti-oestrogen-binding site as a function of time. The dissociation appeared to be monophasic up to 20 min, both in the absence and in the presence of 5, 15 or 25 /LM-oleic acid. In the absence of oleic acid, the time required for 50%o of specifically bound [3H]tamoxifen to dissociate (tL) was 18.5 min, which corresponded to a dissociation rate constant of 6.2 x 10-4 S-1. In the presence of 5, 15 and 25 guM-oleic acid, dissociation was clearly accelerated with ti values of 15.0, 10.5 and 9.5 min respectively. The corresponding dissociation rate constants were 7.7 x 10-4 s-1, 11.0 X 10-4 s-' and 12.2 X 10-4 s-I respectively.
Therefore it would appear that oleic acid increases Fig. 4 were carried out. Fig. 4(a) shows the (Hwang, 1986) non-radioactive tamoxifen (present in 1000-fold molar excess, 2.5 /M), indicating that the anti-oestrogenbinding site emerged at the void-volume peak. As expected, the presence of 500 /tM-oleic acid also abolished this peak; this concentration of oleic acid is known to inhibit completely [3H]tamoxifen binding to the antioestrogen-binding site. When the same experiment was carried out using [3H]oleic acid in place of [3H]tamoxifen, three peaks of radioactivity were observed, with the largest peak emerging at the void volume (Fig. 4b) . The void-volume peak, however, did not appear to represent radioactivity bound to the anti-oestrogen-binding site because it remained unchanged in the presence of a 4000-fold molar excess of non-radioactive tamoxifen (25 /M), an amount known to be far in excess of that required to saturate all the anti-oestrogen-binding sites present. This observation clearly indicates that although [3H]oleic acid may bind to several different macromolecules in the liver supernatant, as suggested by the several peaks of radioactivity seen in gel filtration, the anti-oestrogen-binding site is not one of these. The failure of non-radioactive tamoxifen to displace [3H] oleic acid emerging at the void volume cannot be due to [3H]oleic acid having a higher affinity for the antioestrogen-binding site, since it has been previously demonstrated that oleic acid is only about 0.010% as potent at non-radioactive tamoxifen in displacing [3H]tamoxifen from this site (Hwang, 1986 that the anti-oestrogen-binding sites are located in microsomal membranes (Sudo-et at, 1983) , which, like other cell membranes, have a lipid bilayer as part of their structure. Secondly, it is known that fatty acids intercalate readily into the lipid bilayers of cell membranes.. This, in turn, is believed to result in alterations in membrane structure and in the function of membrane-bound proteins such as receptors and enzymes (Karnovsky et al., 1982; Stubbs & Smith, 1984; Spector & Yorek, 1985) . In this regard, unsaturated fatty acids have been noted to be generally more effective than saturated fatty acids and cis-unsaturated fatty acids more effective than trans-unsaturated fatty acids in altering membrane structure and function. There appears to be a similar order of potency among fatty acids with regard to their inhibitory effect on [3HJtamoxifen binding. Unsaturated fatty acids, for example, have been shown to be much more potent than saturated fatty acids in inhibiting [3H]tamoxifen binding to the anti-oestrogenbinding site (Hwang, 1986 (1983) , who specifically examined the interaction between '4C-labelled fatty acids and rat liver microsomal membranes. They noted that the microsomal membranes did not contain high-affinity saturable binding sites -for fatty acids and that the 'binding' of fatty acids by these membranes was a non-saturable process which could best be explained by partitioning into the lipid phase. This is also a likely explanation for our observation that when [3H]oleic acid was preincubated with the rat liver supernatant and gel filtration carried out as described in Fig. 4 Although these observations were consistent with the suggestion that unsaturated fatty acids inhibit [3H]tamoxifen binding by a non-competitive mechanism, possibly via perturbation of membrane structure, the evidence must be viewed as tentative, because the binding studies were carried out with crude liver extracts and not with purified anti-oestrogen-binding sites. A direct demonstration of the mechanism of fatty acid inhibition of [3H]tamoxifen binding will require the isolation of the anti-oestrogen-binding sites.
The biological significance of the effect of fatty acids on [3H] tamoxifen binding is at present unknown, and speculation is difficult because the function of the anti-oestrogen-binding site remains obscure. It is worth noting, however, that Brandes & Bogdanovic (1986) reported studies suggesting that this site may mediate, at least in part, the antiproliferative effect of a synthetic diphenylmethane derivative, NN-diethyl-2-[(4-phenylmethyl)phenoxy]ethanamine hydrochloride. This compound binds with high affinity to the anti-oestrogen-binding site but does not bind to the oestrogen receptor. Nevertheless, it inhibits oestrogenstimulated growth of the rat uterus in vivo (Brandes & Bogdanovic, 1986 ) and the growth of MCF-7 human breast-cancer cells in vitro (Brandes, 1984) . These findings suggested to Brandes & Bogdanovic (1986) that the anti-oestrogen-binding site might possibly be involved in the regulation of cell growth and proliferation. Similarly, the studies by Runge et al. (1986) also suggested that the inhibitory effect of tamoxifen and its metabolites on the growth of human ovarian cancer cells in culture may be mediated by the anti-oestrogen-binding site and not by the oestrogen receptor. It has long been known from both experimental and epidemiological studies that unsaturated fatty acids enhance the growth of a number of animal and human tumours (Committee on Diet, Nutrition and Cancer, National Research Council, 1982) . The possibility clearly exists that the effects of fatty acids on cellular growth may be related to their interaction with the anti-oestrogen-binding site.
